<DOC>
	<DOCNO>NCT00471965</DOCNO>
	<brief_summary>Primary : - Overall Survival ( OS ) Secondary : - Time Tumor Progression ( TTP ) - Response Rate ( RR ) - Improvement Quality Life ( QoL ) - Safety - Secondary resection rate</brief_summary>
	<brief_title>Oxaliplatin + 5-FluoroUracil/LeucoVorin ( 5-FU/LV ) ( FOLFOX4 ) Versus Doxorubicin Palliative Chemotherapy Advanced Hepatocellular Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically , cytologically clinically diagnose ( patient cirrhosis , AlphaFetoprotein ( AFP ) ≥400μg/L morphological evidence [ contrast Computed Tomography ( CT ) /Magnetic Resonance Imaging ( MRI ) ] hypervascular liver tumor , elevate AFP level due reason [ germ cell carcinoma , progressive chronic hepatitis , pregnancy , etc ] exclude ) unresectable hepatocellular carcinoma , ineligible patient consent receive local invasive treatment ( chemoembolism , ablation , etc. ) . At least one measurable lesion ( CT : ≥2cm , spiral CT MRI ≥1cm ) Have receive previous palliative systemic chemotherapy metastatic disease . If patient receive previous systemic chemotherapy adjuvant treatment , must complete least 12 month previously . Patients progress previous local treatment time randomization least 4 week last interventional therapy ( Hepatic Artery Infusion , TransArtery Embolization TransArtery ChemoEmbolization ) least 8 week last radiotherapy/ablation/ Percutaneous Ethanol Injection target lesion . Karnofsky Performance Score≥70 , Barcelona Cancer Liver Category stage B/C Patients must adequate organ marrow function : Neutrophilus≥1.5X10^9/L Platelets≥75X10^9/L Asparagine AminoTransferase , Alanine AminoTransferase &lt; 2.5 Upper Normal Limit ( UNL ) Total Bilirubin &lt; 1.5 UNL International Normalized Ratio &lt; 1.5 Child stage A B Normal base line Left Ventricular Ejection Fraction ( LVEF result must equal low limit normal institution ) Documented allergy platinum compound study drug . Any previous oxaliplatin doxorubicin treatment , except adjuvant treatment 12 month randomization . Previous liver transplantation . Patients concomitantly receive anticancer therapy , include interferonα herbal medicine approve local authority use `` anticancer '' medicine , except radiotherapy nontarget lesion ( bone metastasis , etc ) Patients receive study treatment . Pregnant lactate woman woman childbearing potential without proper contraceptive method . History malignant disease , except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix . Central nervous system metastasis Other serious illness medical condition The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>